| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
AstraZeneca asthma treatment wins regulatory nod in China
StockMarketWire.com
|
Pharmaceutical giant AstraZeneca said its dual combination asthma treatment had been approved in China.
The company's anti-inflammatory reliever, Symbicort Turbuhaler, was approved in China as a treatment to 'achieve asthma control in patients with mild asthma aged 12 years and older,' the company said.
The approval was based on positive results from the SYGMA 1 and SYGMA 2 phase 3 trials, which evaluated the efficacy of Symbicort Turbuhaler taken as-needed as an anti-inflammatory reliever compared with standard of care therapies in mild asthma.
Story provided by StockMarketWire.com
|
|
|
|
|
|
